PM Tracker

With the monkeypox case count in the U.S. now more than 20,000 and infections spreading to more remote outposts, the Biden administration is bolstering its vaccine and treatment distribution effort with a contract with AmerisourceBergen. The deal will expand the number of weekly shipments and delivery locations of Bavarian Nordic’s Jynneos vaccine and Siga’s TYPOXX med.

Roche has paid out $250 million cash to acquire Good Therapeutics as part of a bid to bolster its immuno-oncology efforts with the Seattle biotech's preclinical PD-1-regulated IL-2 program.

The trouble seemingly never ends for Philips’ beleaguered Respironics division.

This week on "Podnosis," we talk about the changing landscape in the femtech sector after the Dobbs decision. We also chat about health policy issues that impact underserved patient populations.

It’s a good day to be the CFO of SpringWorks Therapeutics. The precision medicine biotech has not only secured $225 million in funding, but also banked a further $75 million equity investment as part of an expanded agreement with GSK.

Once again, England's drug cost watchdog has rejected AstraZeneca and Merck's Lynparza in prostate cancer after failing to reach a price agreement. The final decision created a rift between authorities in the U.K.

A federal jury said Mark Schena, president of Arrayit, misled investors and participated in a kickback scheme that covered more than $77 million in false orders for COVID-19 and allergy tests.

CVS Health has taken the first step in its bid to branch further into healthcare services with its acquisition of Signify Health, executives said Tuesday.

Brickell Biotech is shedding its old name to pursue Fresh Tracks, rebranding in efforts to represent a potential evolution into a clinical-stage pharmaceutical company.

Catalent will expand its clinical supply facility in Singapore. A $2.2 million investment will provide an additional 31,000 square feet, representing a 20% increase in floor space. It will allow for the addition of 35 ultra-low temperature freezers.

A new biotech buoyed by Beam Therapeutics is taking flight, focused on RNA-based medicines. Orbital Therapeutics is launching with an undisclosed amount of money from top investors including a16z and Arch.

Otolith Labs is staying steady with a nerve-stimulating wearable device that aims to relieve the symptoms of chronic vertigo. It already has the FDA’s ear since earning the agency’s breakthrough designation last year.

How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation

Today’s healthcare systems are adapting to an ever changing landscape with declining margins, M&A pressures, and the need for staff flexibility due to shortages. Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens.

This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series).

Improve your congress competitive intelligence and cut down costs by 50%

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Set a solid foundation for successful scale-up of buffer preparation.

Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.